Intelligent Bio Solutions Inc. (NASDAQ: INBS), a leader in non-invasive medical testing technologies, has announced a major contract win with one of London's largest public transport operators. This agreement will see the deployment of INBS's Intelligent Fingerprinting Drug Screening System across 14 sites, impacting over 4,400 staff members and a bus network that serves more than one million passengers daily. The system's ability to provide rapid drug test results in under ten minutes represents a significant advancement in ensuring workplace safety and efficiency.
The contract underscores the effectiveness of INBS's technology in minimizing downtime and reducing costs, key factors for large-scale operations like public transport networks. With over 450 accounts in 24 countries already utilizing its system, INBS is setting a new standard for drug screening in safety-critical industries. The company's planned entry into the U.S. market in 2025, pending FDA clearance, could further expand its global footprint and influence.
For more details on INBS's innovative drug screening solutions, visit https://ibn.fm/E7zJp. This development not only marks a significant milestone for INBS but also highlights the increasing importance of rapid, non-invasive testing technologies in maintaining public safety and operational efficiency in high-stakes environments.
